Australië - Engels - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nimodipine, quantity: 0.2 mg/ml - injection, intravenous infusion - excipient ingredients: ethanol; macrogol 400; sodium citrate dihydrate; citric acid; water for injections - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus (eg hunt and hess grades i-iii).

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

onelink - nifedipine 30mg;  ;   - modified release tablet - 30 mg - active: nifedipine 30mg     excipient: carbomer 934p colloidal silicon dioxide hypromellose   iron oxide red lactose monohydrate macrogol 4000 magnesium stearate   methacrylic acid copolymer povidone purified talc   titanium dioxide - treatment of mild to moderate hypertension.

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - nimodipine - oral suspension - 6mg/1ml

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - nimodipine - oral suspension - 12mg/1ml

Verenigde Staten - Engels - NLM (National Library of Medicine)

azurity pharmaceuticals, inc. - nimodipine (unii: 57wa9qz5wh) (nimodipine - unii:57wa9qz5wh) - nymalize is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., hunt and hess grades i-v). none. risk summary there are no adequate data on the developmental risk associated with the use of nymalize in pregnant women. in animal studies, oral administration of nimodipine during pregnancy resulted in adverse effects on development (increased embryofetal mortality, increased incidences of fetal structural abnormalities, decreased fetal growth) at doses equivalent to (rat) or less than (rabbit) those used clinically [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. d

Malta - Engels - Medicines Authority

bayer plc - nimodipine - solution for infusion or injection - nimodipine 0.02 % (w/v) - calcium channel blockers

Malta - Engels - Medicines Authority

bayer limited 1st floor the grange offices the grange brewery road stillorgan co. dublin, a94 h2k7 , ireland - nimodipine - concentrate for solution for infusion - nimodipine 0.2 mg/ml - calcium channel blockers

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nimodipine 30mg - film coated tablet - 30 mg - active: nimodipine 30mg excipient: crospovidone hypromellose iron oxide yellow macrogol 4000 magnesium stearate maize starch microcrystalline cellulose povidone titanium dioxide - after a preceding infusion of nimotop concentrated intravenous infusion solution, for:- prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin. patients should be in good neurological condition post-ictus.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nimodipine 0.2 mg/ml - solution for infusion - 0.2 mg/ml - active: nimodipine 0.2 mg/ml excipient: citric acid ethanol macrogol 400 sodium citrate dihydrate water for injection - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin. patients should be in good neurological condition post-ictus.

Ierland - Engels - HPRA (Health Products Regulatory Authority)

bayer limited - nimodipine - film-coated tablet - 30 milligram(s) - dihydropyridine derivatives; nimodipine